VIDEX EC Drug Patent Profile

When do Videx Ec patents expire, and when can generic versions of Videx Ec launch?

Videx Ec is a drug marketed by Bristol Myers Squibb and is included in one NDA.

The generic ingredient in VIDEX EC is didanosine. There are eight drug master file entries for this compound. Additional details are available on the didanosine profile page.

Summary for VIDEX EC

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	124
Patent Applications:	4,330
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for VIDEX EC
What excipients (inactive ingredients) are in VIDEX EC?	VIDEX EC excipients list
DailyMed Link:	VIDEX EC at DailyMed

See drug prices for VIDEX EC

Anatomical Therapeutic Chemical (ATC) Classes for VIDEX EC

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for VIDEX EC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIDEX EC	Delayed-release Capsules	didanosine	200 mg, 250 mg and 400 mg	021183	1	2004-06-01

US Patents and Regulatory Information for VIDEX EC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-001	Oct 31, 2000		DISCN	Yes	No
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-004	Oct 31, 2000		DISCN	Yes	No
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-002	Oct 31, 2000		DISCN	Yes	No
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-003	Oct 31, 2000		DISCN	Yes	No

Expired US Patents for VIDEX EC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-004	Oct 31, 2000
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-002	Oct 31, 2000
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-002	Oct 31, 2000
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-001	Oct 31, 2000
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-004	Oct 31, 2000
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-003	Oct 31, 2000
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-003	Oct 31, 2000

International Patents for VIDEX EC

See the table below for patents covering VIDEX EC around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	32294
Israel	79700	ANTIVIRAL COMPOSITIONS CONTAINING 2',3'-DIDEOXYINOSINE,2',3'-DIDEOXYGUANOSINE OR 2',3'-DIDEOXYADENOSINE OR PHOSPHATES THEREOF AND THEIR USE IN A METHOD FOR ALLEVIATING THE CYTOPATHIC EFFECTS OF HTLV-III VIRUS ON CELLS IN VITRO
European Patent Office	0216510	Inhibition de l'infectivité in vitro et de l'effet cytopathique du HTLV-III/LAV par la 2'3'-didéoxyinosine, la 2'3'-didéoxyguanosine ou par la 2'3'-didéoxyadénosine. (Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine.)
Germany	3689220
European Patent Office	0472663
Netherlands	940005
Mexico	9203377	COMPOSICIONES ANTIVIRALES.

Supplementary Protection Certificates for VIDEX EC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0216510	SPC/GB94/005	United Kingdom		SPC/GB94/005:, EXPIRES: 20070504
0285237	94C0006	France		PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
0216510	SZ 54/1994	Austria		PRODUCT NAME: 2',3'-DIDEOXYINOSIN
0216510	94C0006	Belgium		PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505